Compare ACEL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.7M | 856.4M |
| IPO Year | 2017 | 2020 |
| Metric | ACEL | DRUG |
|---|---|---|
| Price | $10.93 | $89.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.00 | ★ $114.00 |
| AVG Volume (30 Days) | ★ 280.1K | 89.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | $26.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.02 | $23.18 |
| 52 Week High | $12.92 | $123.75 |
| Indicator | ACEL | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 59.64 |
| Support Level | $10.13 | $73.97 |
| Resistance Level | $11.63 | $97.75 |
| Average True Range (ATR) | 0.28 | 5.78 |
| MACD | -0.03 | 1.33 |
| Stochastic Oscillator | 16.35 | 88.69 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.